Diabetes drugs linked to fewer complications after valve replacement
An observational study of 9,930 people with diabetes linked drug use after aortic valve replacement to fewer cardiovascular complications and deaths for up to one year.
Limit: Defining exposure after valve replacement could favor patients surviving long enough to receive treatment
Edited by Boris Djordjevic · AgingResearch.News
Researchers analyzed records from 9,930 people with diabetes who had undergone transcatheter aortic valve replacement, a procedure that replaces the valve through a catheter. In this retrospective observational study, they matched two groups on patient characteristics and compared outcomes by exposure to sodium-glucose cotransporter-2 inhibitors, a class of diabetes drugs. Exposure meant use after the first day following valve replacement.
People exposed to the drugs had lower risks of major heart and blood vessel events and death from cardiovascular causes at one month and one year. They also had lower risks of strokes caused by blocked blood vessels and worsening heart failure, a condition in which the heart cannot pump enough blood to meet the body’s needs.
Why it matters
Heart failure can complicate aortic valve replacement, a procedure often used in older or high-risk patients. The study addresses whether drugs already recommended for heart failure may also have a role after valve replacement.
Caveats
This observational comparison cannot show that the drugs caused the lower risks. The findings concern people with diabetes after this valve procedure, not people without diabetes.
The paper
Journal of the Society for Cardiovascular Angiography & Interventions, Aug 13, 2026, Open access
